Edwards Lifesciences Statistics
Share Statistics
Edwards Lifesciences has 585.75M
shares outstanding. The number of shares has increased by -2.8%
in one year.
| Shares Outstanding | 585.75M |
| Shares Change (YoY) | -2.8% |
| Shares Change (QoQ) | -0.69% |
| Owned by Institutions (%) | 84.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 163 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 7.93M, so 1.35% of the outstanding
shares have been sold short.
| Short Interest | 7.93M |
| Short % of Shares Out | 1.35% |
| Short % of Float | 1.54% |
| Short Ratio (days to cover) | 1.5 |
Valuation Ratios
The PE ratio is 10.6 and the forward
PE ratio is 27.47.
Edwards Lifesciences's PEG ratio is
0.05.
| PE Ratio | 10.6 |
| Forward PE | 27.47 |
| PS Ratio | 8.13 |
| Forward PS | 5.2 |
| PB Ratio | 4.43 |
| P/FCF Ratio | 152.63 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Edwards Lifesciences has an Enterprise Value (EV) of 41.9B.
| EV / Sales | 7.7 |
| EV / EBITDA | 24.32 |
| EV / EBIT | 77.27 |
| EV / FCF | 144.54 |
Financial Position
The company has a current ratio of 4.18,
with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.18 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 2.41 |
| Interest Coverage | 69.63 |
Financial Efficiency
Return on Equity is 41.75% and Return on Invested Capital is 10.72%.
| Return on Equity | 41.75% |
| Return on Assets | 31.98% |
| Return on Invested Capital | 10.72% |
| Revenue Per Employee | $344,272.15 |
| Profits Per Employee | $264,215.19 |
| Employee Count | 15,800 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.03 |
Taxes
| Income Tax | 152.1M |
| Effective Tax Rate | 9.82% |
Stock Price Statistics
The stock price has increased by -11.62% in the
last 52 weeks. The beta is 1.15, so Edwards Lifesciences's
price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | -11.62% |
| 50-Day Moving Average | 71.38 |
| 200-Day Moving Average | 70.3 |
| Relative Strength Index (RSI) | 59.2 |
| Average Volume (20 Days) | 4,823,625 |
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 5.44B
and earned 4.17B
in profits. Earnings per share was 6.98.
| Revenue | 5.44B |
| Gross Profit | 4.32B |
| Operating Income | 1.38B |
| Net Income | 4.17B |
| EBITDA | 1.72B |
| EBIT | 1.57B |
| Earnings Per Share (EPS) | 6.98 |
Full Income StatementBalance Sheet
The company has 3.05B in cash and 700M in
debt, giving a net cash position of 2.35B.
| Cash & Cash Equivalents | 3.05B |
| Total Debt | 700M |
| Net Cash | 2.35B |
| Retained Earnings | 13.17B |
| Total Assets | 13.06B |
| Working Capital | 4.78B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 542.3M
and capital expenditures -252.4M, giving a free cash flow of 289.9M.
| Operating Cash Flow | 542.3M |
| Capital Expenditures | -252.4M |
| Free Cash Flow | 289.9M |
| FCF Per Share | 0.49 |
Full Cash Flow StatementMargins
Gross margin is 79.46%, with operating and profit margins of 25.35% and 76.75%.
| Gross Margin | 79.46% |
| Operating Margin | 25.35% |
| Pretax Margin | 28.46% |
| Profit Margin | 76.75% |
| EBITDA Margin | 31.68% |
| EBIT Margin | 25.35% |
| FCF Margin | 5.33% |
